pharma · Moderately to Severely Active Rheumatologic Disease · Moderately to Severely Active Ulcerative Colitis · SYRE
Spyre Therapeutics
Spyre Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker SYRE. Primary therapeutic focus areas include Moderately to Severely Active Rheumatologic Disease, Moderately to S
Waltham, USA HQ
2023 Founded
110 Employees
Public company Type
SYRE · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2023
- Employees
- 110
- Programs
- 8
- Drugs
- 1
- Patents
- 0
SPY002-072
Phase 2 · small molecule · Rheumatoid Arthritis
SPY002-072 for Rheumatoid Arthritis is a Phase 2 program (small_molecule) at Spyre Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code SPY002-072-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Spyre Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Rheumatoid Arthritis
- Status
- active
- Trials
- 1